Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galvokimig in Moderate-to-Severe COPD With Chronic Bronchitis
NCT07725939Phase 2Recruiting
- Sponsor
- UCB
- Start
- Jul 2026
- Primary completion
- Jun 2029
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of galvokimig in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by UCB. Primary endpoint: Time from treatment assignment to first moderate or severe acute exacerbation of chronic obstructive pulmonary disease at 60 weeks. Started Jul 2026; status: recruiting.
02
Drugs
galvokimig
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07725939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07725939.